Nemaura Competitors

Summary

NMRDDelisted Stock

USD 0.93 0.01 1.06%

Nemaura Medical competes with Neuropace, CVRx, Orthofix Medical, Artivion, and Bluejay Diagnostics; as well as few others. The company conducts business under Health Care Equipment & Supplies sector and is part of Health Care industry. Analyzing Nemaura Medical competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Nemaura Medical to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Nemaura Medical competition on your existing holdings.

Specify up to 10 symbols:

Hype

Prediction

Low	Estimated	High
0.93	0.93	0.93

Details

Intrinsic

Valuation

Low	Real	High
0.74	0.74	1.02

Details

Nemaura Medical Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Nemaura Medical and its competitors represents the degree of relationship between the price movements of corresponding pink sheets. A correlation of about +1.0 implies that the price of Nemaura and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Nemaura Medical does not affect the price movement of the other competitor.

	NPCE	CVRX	OFIX	AORT	HSKA	BJDX	MOVE	INVO	NVNO	MODD
NPCE		0.61	0.73	0.78	0.42	-0.58	0.29	0.4	-0.44	-0.9	NPCE
CVRX	0.61		0.92	0.78	0.62	-0.71	-0.32	0.04	-0.24	-0.47	CVRX
OFIX	0.73	0.92		0.83	0.61	-0.72	-0.17	0.19	-0.25	-0.58	OFIX
AORT	0.78	0.78	0.83		0.64	-0.64	0.21	0.12	-0.53	-0.73	AORT
HSKA	0.42	0.62	0.61	0.64		-0.79	-0.27	-0.24	-0.59	-0.49	HSKA
BJDX	-0.58	-0.71	-0.72	-0.64	-0.79		0.35	-0.06	0.54	0.6	BJDX
MOVE	0.29	-0.32	-0.17	0.21	-0.27	0.35		0.17	-0.14	-0.34	MOVE
INVO	0.4	0.04	0.19	0.12	-0.24	-0.06	0.17		0.05	-0.38	INVO
NVNO	-0.44	-0.24	-0.25	-0.53	-0.59	0.54	-0.14	0.05		0.63	NVNO
MODD	-0.9	-0.47	-0.58	-0.73	-0.49	0.6	-0.34	-0.38	0.63		MODD
	NPCE	CVRX	OFIX	AORT	HSKA	BJDX	MOVE	INVO	NVNO	MODD

Click cells to compare fundamentals

Check Volatility

Backtest Portfolio

Please upgrade your account to get full access to Macroaxis premium features

High positive correlations

OFIX	+ 0.92	CVRX
AORT	+ 0.83	OFIX
AORT	+ 0.78	NPCE
AORT	+ 0.78	CVRX
OFIX	+ 0.73	NPCE
HSKA	+ 0.64	AORT

High negative correlations

MODD	- 0.9	NPCE
BJDX	- 0.79	HSKA
MODD	- 0.73	AORT
BJDX	- 0.72	OFIX
BJDX	- 0.71	CVRX
BJDX	- 0.64	AORT

Risk-Adjusted Indicators

There is a big difference between Nemaura Pink Sheet performing well and Nemaura Medical Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Nemaura Medical's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.

	Mean Deviation	Jensen Alpha	Sortino Ratio	Treynor Ratio	Semi Deviation	Expected Shortfall	Potential Upside	Value @Risk	Maximum Drawdown
NPCE	3.67	0.75	0.21	0.36	3.04	(4.39)	9.73	(6.20)	35.79
CVRX	3.62	0.54	0.12	0.50	3.77	(4.24)	9.25	(8.95)	41.08
OFIX	1.66	0.09	0.05	0.09	1.88	(1.84)	3.87	(3.15)	12.11
AORT	1.27	0.16	0.11	0.14	1.44	(1.36)	2.86	(2.42)	9.51
HSKA	1.18	0.59	0.99	1.65	0.00	(1.25)	3.63	(0.71)	21.36
BJDX	8.62	0.06	0.00	(0.07)	11.28	(9.87)	14.89	(15.29)	120.57
MOVE	5.02	0.34	0.06	0.18	5.97	(6.10)	11.06	(9.04)	61.96
INVO	4.97	0.39	0.07	1.36	4.69	(8.22)	6.67	(6.85)	105.62
NVNO	2.86	(0.99)	0.00	(1.32)	0.00	0.00	3.99	(6.65)	29.78
MODD	2.06	(0.70)	0.00	2.50	0.00	0.00	2.79	(4.76)	17.34

Unable to evaluate fundamental data of [NPCE, CVRX, OFIX, AORT, HSKA, BJDX, MOVE, INVO, NVNO, MODD, NXL, SSKN, AIMDW, ELMD, ARMM, SRDX] at this time. Please try again later

All Fundamental Data

Nemaura Medical Competitive Analysis

The better you understand Nemaura Medical competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Nemaura Medical's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Nemaura Medical's competition over several years is one of the best ways to analyze its investment potential.

Better Than Average

Worse Than Peers

View Performance Chart

	NMRD	NPCE	CVRX	OFIX	AORT	HSKA	BJDX	MOVE	INVO	NVNO
	1.06 0.93 Nemaura	3.50 11.53 Neuropace	3.33 12.11 CVRx	1.40 17.43 Orthofix	1.82 28.48 Artivion	0.00 119.99 Heska	1.54 3.84 Bluejay	6.20 5.65 Movano	3.45 0.84 INVO	1.58 2.49 EnVVeno
Market Volatility (90 Days Market Risk)	Very steady	Slightly risky	Somewhat reliable	Very steady	Very steady	Very steady	Extremely Dangerous	Dangerous	Out of control	Slightly risky
Market Performance (90 Days Performance)	Very Weak	Good	OK	Modest	OK	Very Weak	Very Weak	Insignificant	Modest	Very Weak
Odds of Financial Distress (Probability Of Bankruptcy)	Dangerous	Quite High	Below Average	Low	Below Average	Dangerous	Very High	Low	Dangerous	Low
Current Valuation (Equity Enterprise Value)	Over Valued	Over Valued	Under Valued	Under Valued	Fairly Valued	Over Valued	Fairly Valued	Over Valued	Fairly Valued	Under Valued
Buy or Sell Advice (Average Analysts Consensus)	Not Available	Strong Buy	Strong Buy	Buy	Strong Buy	Not Available	Not Available	Buy	Not Available	Strong Buy
Trade Advice (90 Days Macroaxis Advice)	Not Rated	Hold	Cautious Hold	Hold	Strong Hold	Not Rated	Strong Sell	Strong Sell	Not Rated	Strong Sell
Current Ratio	0.99	9.86	16.82	3.15	5.77	6.92	17.41	6.78	1.99	20.79
Net Asset	14.56 M	107.65 M	115.23 M	925.32 M	792.4 M	585.82 M	4.87 M	9.42 M	20.89 M	48.63 M
Profit Margin	N/A	-0.37	-1.24	-0.15	-0.0022	-0.0786	N/A	N/A	-1.23	N/A
EBITDA	(8.17 M)	(22.83 M)	(43.1 M)	(79.45 M)	26.87 M	(20.3 M)	(9.17 M)	(29.12 M)	(6.63 M)	(25.02 M)
Current Valuation	22.58 M	360.82 M	244.11 M	773.25 M	1.5 B	652.94 M	(3.35 M)	26.31 M	15.19 M	(3.37 M)
Price To Book	122.56	35.03	4.51	1.27	3.92	1.74	0.3	3.66	5.97	0.93
Operating Margin	N/A	-0.2	-0.97	-0.0861	0.0826	-0.094	N/A	-31.99	-1.04	N/A
Retained Earnings	(51.88 M)	(503.81 M)	(477.38 M)	(150.14 M)	(47.91 M)	(168.53 M)	(26.95 M)	(124.38 M)	(57.82 M)	(130.04 M)
Current Asset	9.55 M	N/A	N/A	147.87 M	N/A	41.26 M	N/A	138.64 M	N/A	N/A
Beta	0.046	1.8	1.11	1.05	1.75	1.6	0.73	0.19	1.44	1.22
Number Of Employees	36	184	200	1.63 K	1.5 K	808	10	30	25	31
Shares Outstanding	28.9 M	29.85 M	24.26 M	38.21 M	41.92 M	10.91 M	552.85 K	6.6 M	3.91 M	17.54 M
Cash Flow From Operations	(8.45 M)	(19.7 M)	(39.02 M)	(45.75 M)	18.82 M	(21.81 M)	(8.31 M)	(26.18 M)	(4.76 M)	(18.86 M)
Total Debt	20.03 M	72.39 M	30.61 M	134.2 M	358.34 M	95.6 M	352.98 K	217 K	8.68 M	1.4 M
Return On Equity	-7.24	-2.15	-0.79	-0.21	-0.0029	-0.0473	-1.25	-1.81	-143.59	-0.59
Z Score	-7.48	N/A	N/A	N/A	N/A	8.6	N/A	N/A	N/A	N/A
Return On Asset	-0.49	-0.15	-0.31	-0.0237	0.0229	-0.0251	-0.59	-0.89	-0.27	-0.37
Number Of Shares Shorted	52.57 K	249.42 K	1.95 M	1.37 M	3.35 M	1.32 M	6.8 K	70.94 K	1.95 K	479.08 K
Book Value Per Share	-0.55	0.33	2.69	13.76	7.27	38.26	18.69	2.54	-1.59	2.7
Current Liabilities	658.01 K	N/A	N/A	52.94 M	N/A	18.8 M	N/A	40.62 M	N/A	N/A
Total Asset	14.56 M	107.65 M	115.23 M	925.32 M	792.4 M	585.82 M	4.87 M	9.42 M	20.89 M	48.63 M
Short Ratio	0.3	2.85	5.33	3.89	13.95	5.41	0.09	3.76	0.04	4.12
Target Price	3.5	16.17	18.17	24.4	33.17	130.0	256.0	30.0	20.0	18.0
Debt To Equity	N/A	1.08	0.003	0.078	1.27	0.26	0.036	0.025	0.6	0.04
Shares Owned By Institutions	7.7	82.87	71.88	92.2	87.61	87.54	0.95	13.84	3.0	29.76
Market Capitalization	2.43 M	344.15 M	293.83 M	666.07 M	1.19 B	1.31 B	2.12 M	27.72 M	3.25 M	43.66 M
Price To Earning	-707.14	N/A	0.19	338.0	N/A	498.39	N/A	39.53	N/A	N/A
Price To Earnings To Growth	N/A	N/A	N/A	0.33	181.5	2.53	N/A	N/A	N/A	N/A
Price To Sales	804.62	4.5	6.22	0.85	3.1	2.6	54.99	43.99	0.56	N/A
Net Income	(14.14 M)	(32.96 M)	(41.2 M)	(151.4 M)	(30.69 M)	(19.89 M)	(9.95 M)	(29.28 M)	(8.03 M)	(23.52 M)
Earnings Per Share	-0.39	-0.98	-2.69	-3.14	-0.03	-1.92	-804.0	-5.8	0.69	-1.29
Shares Owned By Insiders	48.3	4.1	4.39	4.99	5.47	6.45	1.14	17.33	0.6	0.3
Revenue	77.04 K	65.42 M	39.3 M	746.64 M	354 M	257.31 M	N/A	N/A	3.02 M	N/A
Working Capital	(8.73 M)	76.49 M	104.23 M	255.22 M	222.81 M	225.46 M	1.45 M	2.62 M	(6.96 M)	45.55 M
Cash And Equivalents	14.75 M	92.41 M	109.98 M	59.54 M	40.38 M	171.93 M	15.34 M	21.3 M	1.96 M	37.48 M
Cash Per Share	0.61	3.72	5.34	2.98	1.0	15.89	0.76	0.65	0.16	3.96
Gross Profit	(1.48 M)	32.49 M	17.47 M	337.17 M	202.52 M	111.17 M	48.91 K	N/A	535.27 K	N/A
Day Typical Price	0.94	11.29	11.93	17.37	28.34	119.99	3.9	5.49	0.84	2.56
Accumulation Distribution	0.1	0.0716	0.0725	0.0522	0.0392	N/A	0.099	0.0935	0.0805	0.11
Market Facilitation Index	0.1	0.83	0.89	0.93	1.13	N/A	0.41	0.53	0.07	0.29
Daily Balance Of Power	(0.10)	0.4699	0.4382	0.2581	0.4513	0.0	(0.15)	0.6226	(0.43)	(0.14)
Period Momentum Indicator	(0.01)	0.39	0.39	0.24	0.51	N/A	(0.06)	0.33	(0.03)	(0.04)
Rate Of Daily Change	0.99	1.04	1.03	1.01	1.02	1.0	0.98	1.06	0.97	0.98
Day Median Price	0.95	11.18	11.84	17.34	28.27	119.99	3.93	5.4	0.84	2.6
Price Action Indicator	(0.03)	0.55	0.47	0.21	0.47	N/A	(0.12)	0.41	(0.01)	(0.12)
Coefficient Of Variation	2006.49	666.32	1047.67	1724.92	833.38	452.21	30005.44	2157.34	2968.94	(481.08)
Mean Deviation	4.82	3.67	3.62	1.66	1.27	1.18	8.62	5.02	4.97	2.86
Jensen Alpha	0.3399	0.7503	0.5388	0.0856	0.1626	0.5883	0.0593	0.343	0.3909	(0.99)
Total Risk Alpha	0.1421	0.6486	0.3955	0.0541	0.1458	0.5196	(0.41)	0.1489	0.0587	(1.10)
Sortino Ratio	0.0529	0.209	0.1219	0.0465	0.1062	0.993	0.0019	0.0566	0.0708	N/A
Downside Variance	35.41	13.83	19.76	3.9	2.59	0.3343	138.89	42.58	28.13	N/A
Standard Deviation	6.97	5.39	6.01	2.14	1.69	2.74	16.29	8.66	12.1	4.64
Kurtosis	2.18	9.12	10.01	0.6899	1.21	44.83	14.81	16.22	43.34	17.23
Potential Upside	14.29	9.73	9.25	3.87	2.86	3.63	14.89	11.06	6.67	3.99
Treynor Ratio	(2.87)	0.3595	0.4976	0.0888	0.1398	1.65	(0.07)	0.179	1.36	(1.32)
Maximum Drawdown	35.66	35.79	41.08	12.11	9.51	21.36	120.57	61.96	105.62	29.78
Variance	48.54	29.1	36.15	4.58	2.87	7.52	265.26	75.01	146.3	21.52
Market Risk Adjusted Performance	(2.86)	0.3695	0.5076	0.0988	0.1498	1.66	(0.06)	0.189	1.37	(1.31)
Risk Adjusted Performance	0.0483	0.1274	0.0843	0.0522	0.1004	0.1823	0.0122	0.0458	0.036	(0.16)
Skewness	1.11	2.15	2.21	0.2689	0.2608	6.25	2.89	2.57	6.01	(2.93)
Semi Deviation	5.23	3.04	3.77	1.88	1.44	0.0	11.28	5.97	4.69	N/A
Information Ratio	0.0452	0.1441	0.0901	0.0429	0.101	0.2094	0.0014	0.0426	0.031	(0.21)
Value At Risk	(9.72)	(6.20)	(8.95)	(3.15)	(2.42)	(0.71)	(15.29)	(9.04)	(6.85)	(6.65)
Expected Short fall	(6.03)	(4.39)	(4.24)	(1.84)	(1.36)	(1.25)	(9.87)	(6.10)	(8.22)	N/A
Downside Deviation	5.95	3.72	4.45	1.97	1.61	0.5782	11.79	6.53	5.3	N/A
Semi Variance	27.4	9.25	14.25	3.54	2.06	(0.46)	127.26	35.63	21.96	N/A

Nemaura Medical Competition Performance Charts

Five steps to successful analysis of Nemaura Medical Competition

Nemaura Medical's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Nemaura Medical in relation to its competition. Nemaura Medical's competition analysis typically involves several steps, including:

Identifying the key players in the market: This involves identifying the major competitors of Nemaura Medical in the market, both direct and indirect, as well as new entrants and disruptive technologies.
Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Nemaura Medical's competitive landscape.
Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Nemaura Medical, and developing a strategy to address them.
Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.

Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Nemaura Medical position

In addition to having Nemaura Medical in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Money Funds Thematic Idea Now

Money Funds

Funds or Etfs that invest most if their asset in companies from financial sector such as commercial banks, insurance companies, investment funds, and real estate. The Money Funds theme has 32 constituents at this time.

You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Money Funds Theme or any other thematic opportunities.

View All Next

Launch

Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.

Other Consideration for investing in Nemaura Pink Sheet

If you are still planning to invest in Nemaura Medical check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Nemaura Medical's history and understand the potential risks before investing.

	Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
	Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
	Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments
	Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC